Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
BURNABY, British Columbia, May 04, 2017 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2017 first quarter financial and operating results after the close of U.S. financial markets on Tuesday, May 9, 2017. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update.
To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 19520816. The webcast will be broadcast live on the “Investors” section of Xenon's website at www.xenon-pharma.com and will be available for replay following the call for 30 days.
About Xenon Pharmaceuticals Inc.
Xenon is a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our pharmaceutical collaborators – a novel product pipeline of ion channel modulators to address therapeutic areas of high unmet medical need, such as pain and epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact: Jodi Regts Senior Director, Corporate Affairs Xenon Pharmaceuticals Inc. Phone: 604.484.3353 Email: [email protected]
